Celularity (NASDAQ: CELU) closes NexGel asset sale as Helena note default looms
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Celularity Inc. updated investors on its divestiture of its biomaterials business to NexGel and new financing developments. An amendment set total consideration at $13.3 million, including $8.3 million cash at closing and a $5.0 million convertible note, plus eligibility for up to $20.0 million in future milestone payments and royalties. The company reports the transaction allowed it to retire nearly $13.0 million of debt as it refocuses on its core cell therapy platform.
Separately, Helena Global exchanged preferred shares for a $1,970,502.58 convertible promissory note bearing 18% interest, maturing on October 16, 2026, and then delivered an event-of-default notice that Celularity believes stems from its late Form 10‑K filing. If uncured within five business days, Helena may accelerate payment of 115% of amounts owed and increase the interest rate to 15% on any outstanding principal. Celularity also announced leadership changes tied to its strategic realignment, including the termination of a senior vice president and the resignation of its president of degenerative diseases.
Positive
- The amended NexGel transaction provides $13.3 million in consideration, including $8.3 million cash and a $5.0 million convertible note, plus eligibility for up to $20.0 million in future milestone payments and royalties.
- Celularity reports the NexGel deal enabled it to retire nearly $13.0 million of debt, which strengthens its balance sheet while it refocuses on its core cell therapy and longevity strategy.
Negative
- Helena Global delivered an event-of-default notice on a $1,970,502.58 convertible note bearing 18% interest, tied to Celularity’s delinquent Form 10‑K, introducing acceleration and penalty-interest risk.
- If Helena’s asserted default is not cured within the five-business-day period specified in the note, Celularity may owe a Mandatory Default Amount equal to 115% of principal, accrued interest and other amounts, increasing financial pressure.
Insights
Debt-heavy financing and a default notice offset balance-sheet relief from the NexGel divestiture.
Celularity closed and amended its biomaterials divestiture to NexGel, locking in $13.3 million of consideration and eligibility for up to $20.0 million in milestones plus royalties. Management highlights that the deal helped retire nearly $13.0 million of debt while refocusing resources on its core cell therapy platform.
However, the company also accepted a $1,970,502.58 Helena convertible note at a steep 18% coupon, with potential default interest of 15% and a 115% Mandatory Default Amount if an asserted default is not cured. The filing links this alleged default to a late Form 10‑K.
This combination signals ongoing balance-sheet stress: expensive capital, tight covenants and execution risk around SEC reporting timeliness. The company states it intends to cure within the five-business-day period under the note, but the ultimate impact depends on whether it successfully remedies the default and maintains access to needed financing.
8-K Event Classification
6 items: 1.01, 2.03, 3.03, 5.02, 8.01, 9.01
6 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 3.03
Material Modification to Rights of Security Holders
Securities
A change was made that materially affects the rights of existing shareholders (e.g., dividend rights, voting rights).
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
NexGel transaction consideration: $13.3 million
NexGel cash payment: $8.3 million
NexGel convertible note: $5.0 million
+5 more
8 metrics
NexGel transaction consideration
$13.3 million
Aggregate consideration under amended asset purchase and license agreement
NexGel cash payment
$8.3 million
Upfront cash on transaction commencement date
NexGel convertible note
$5.0 million
Convertible promissory note with 18‑month term from NexGel
Potential NexGel milestones
Up to $20.0 million
Future milestone payments based on net sales thresholds
Debt retired via transaction
Nearly $13.0 million
Debt reportedly retired through NexGel transaction
Helena note principal
$1,970,502.58
Original principal amount of Helena convertible promissory note
Helena note interest rate
18.0% per annum
Stated coupon on Helena convertible note before default
Mandatory Default Amount multiplier
115%
Percentage of principal, interest and other amounts if default uncured
Key Terms
Convertible Promissory Note, Mandatory Default Amount, milestone payment, royalties, +2 more
6 terms
Convertible Promissory Note financial
"a convertible promissory note in the original principal amount of $5.0 million with an 18-month term"
A convertible promissory note is a loan a company takes now that can later be turned into shares instead of being repaid in cash. Think of it as lending money with the option to accept ownership in the business down the road; that matters to investors because it affects who gets paid first, how much ownership existing shareholders keep, and the company’s future valuation and cash needs. Terms such as conversion price, interest and maturity determine the financial impact.
Mandatory Default Amount financial
"Helena may declare due and payable the “Mandatory Default Amount,” which is equal to 115% of the outstanding principal amount"
milestone payment financial
"the first milestone payment of $2.5 million will be payable upon the earlier of the achievement of $25.0 million in net sales"
A milestone payment is a pre-agreed cash amount paid when a company reaches a specific, measurable achievement in a partnership, such as completing a clinical trial stage, receiving regulatory approval, or hitting a sales target. For investors it signals how future revenue and risk are shared — like progress payments on a construction project, these payments can unlock value and affect a company’s cash flow and valuation as each milestone is met.
royalties financial
"eligible to receive up to $20.0 million in future milestone payments ... and royalties on net sales of certain development-stage products"
Payments made to the owner of an asset or intellectual property each time that asset is used or a product is sold, often calculated as a percentage of sales or a set amount per unit. Royalties matter to investors because they create predictable, ongoing income streams and affect a company’s cash flow and valuation—like a landlord collecting rent or an author getting a steady cut whenever a book is sold.
event of default financial
"Helena delivered to the Company a notice of event of default (the “Default Notice”) under the Helena Note"
An event of default is a specific breach of a loan or bond agreement—such as missed payments or breaking agreed rules—that gives lenders the legal right to act, for example by demanding immediate repayment, seizing collateral, or accelerating other obligations. For investors, it’s a red flag because it can sharply reduce a company’s ability to operate or raise money, like a car lender repossessing a vehicle after missed payments, and often leads to falling share or bond prices.
emerging growth company regulatory
"Emerging growth company Item 1.01. Entry into a Material Definitive Agreement."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did Celularity (CELU) announce about its transaction with NexGel?
Celularity announced closing and amendment of its NexGel transaction, selling biomaterials assets and granting an exclusive license. It receives $13.3 million in total consideration, including $8.3 million cash and a $5.0 million convertible note, plus potential milestones and royalties.
How much consideration does Celularity (CELU) receive from the NexGel deal?
Celularity receives aggregate consideration of $13.3 million from NexGel: an upfront cash payment of $8.3 million at the transaction commencement date and a $5.0 million convertible promissory note with an 18‑month term, along with eligibility for additional milestone and royalty payments.
What future payments could Celularity (CELU) earn from NexGel?
Celularity may receive up to $20.0 million in future milestone payments tied to net sales thresholds, plus royalties on net sales of certain development-stage products. These contingent payments depend on NexGel’s commercial performance and are governed by the transaction documents’ specific sales triggers.
What is the Helena convertible note disclosed by Celularity (CELU)?
Helena exchanged preferred stock for a Celularity convertible promissory note with original principal of $1,970,502.58, bearing 18.0% annual interest and maturing on October 16, 2026, unless earlier converted, prepaid or accelerated according to its terms, including default provisions.
Why did Helena issue a default notice to Celularity (CELU)?
Helena delivered an event-of-default notice alleging one or more defaults under the Helena note, including under Section 2.1(p), which references failure to meet Exchange Act reporting requirements. Celularity believes this stems from its failure to timely file its Form 10‑K for 2025.
What happens if Celularity (CELU) does not cure the Helena note default?
If the asserted default is not cured within the five-business-day cure period, Helena may declare due the Mandatory Default Amount, equal to 115% of outstanding principal, accrued interest and other amounts. Default also increases interest on outstanding principal to 15% annually, compounded.
What leadership changes did Celularity (CELU) disclose in April 2026?
Celularity reported organizational changes tied to its strategic realignment. It terminated Senior Vice President and Chief Administrative Officer John R. Haines without cause, with an expected final employment day of May 8, 2026, and President, Degenerative Diseases Stephen A. Brigido resigned effective immediately on April 15, 2026.